• Emily X Zhang, Cyrus Yazdi, Rahib K Islam, Ahmed I Anwar, Alana Alvares-Amado, Horace Townsend, Kaitlyn E Allen, Elena Plakotaris, Jon D Hirsch, Ross G Rieger, Varsha Allampalli, Jamal Hasoon, Kazi N Islam, Sahar Shekoohi, Alan D Kaye, and Christopher L Robinson.
• Department of Anesthesia, Critical Care and Pain Medicine, Harvard Medical School, Massachusetts General Hospital, Boston, MA, USA.
• Curr Pain Headache Rep. 2024 Oct 1; 28 (10): 106710721067-1072.

Purpose Of ReviewDiabetic neuropathy is a common complication of diabetes mellitus (DM) and can affect up to 50% of DM patients during their lifetime. Patients typically present with numbness, tingling, pain, and loss of sensation in the extremities. Since there is no treatment targeting the underlying mechanism of neuropathy, strategies focus on preventative care and pain management.Recent FindingsUp to 69% of patients with diabetic neuropathy receive pharmacological treatment for neuropathic pain. The United States Food and Drug Administration (FDA) confirmed four drugs for painful diabetic neuropathy (PDN): pregabalin, duloxetine, tapentadol, and the 8% capsaicin patch. Nonpharmacological treatments such as spinal cord stimulation (SCS) and transcutaneous electrical nerve stimulation (TENS) both show promise in reducing pain in DM patients. Despite the high burden associated with PDN, effective management remains challenging. This update covers the background and management of diabetic neuropathy, including its epidemiology, pathogenesis, preventative care, and current therapeutic strategies.© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

18 keywords...

hide…